We Sequence, You Discover.
BGI was founded in 1999 to support the Human Genome Project. Since then, BGI has grown into a multinational genomics company with global operations, including sequencing laboratories based in the US, Europe, Hong Kong, and mainland China. · Next Generation Sequencing Services · Pharma R&D Solutions · Proteomics Services · Bioinformatics Services We operate all common NGS platforms, and exclusively offer the best data quality at the lowest cost from DNA Nanoball Sequencing with the DNBSeq system, developed by BGI’s Complete Genomics subsidiary. · The highest quality data · The quickest turn-around · The lowest cost Our vast experience with Genomics, Proteomics and Bioinformatics positions BGI uniquely to support academia and pharmaceutical companies with highly reliable genomic data for Basic Research and Drug Development.
The transcriptome is the total set of RNA transcripts, mRNAs and non-coding RNAs in one or a population of cells. With next generation sequencing technology, all transcriptional activity, for both coding and non-coding regions, in any organism can be characterized without prior annotation information. This allows the identification of regulatory RNAs, annotation of coding SNPs, determination of the relative abundance of transcripts, and more. BGI provides comprehensive transcriptome sequencing services as well as the bioinformatics expertise essential to conduct extensive analysis of the RNA-Seq data.
Our transcriptomics services include: -
Whole Transcriptome Sequencing
Single-cell RNA Sequencing
BGI is a world-leading provider of Human Whole Exome Sequencing, having sequenced more than 45,000 human exomes to date. Our expertise in human exome sequencing comes from our 15 years of experience doing more whole exome and whole genome sequencing than any institution in the world. Our data analysis prowess is derived from our long history and extensive work in creating innovative and highly effective proprietary approaches and algorithms for analyzing data for genome analysis. We have unparalleled experience and expertise in both the process of large scale NGS sequencing and in analyzing the data generated. In addition to Human Exome Sequencing, we provide mouse exome sequencing service using Agilent Mouse All Exon kit and developed a platform for sequencing the exome of monkeys based on our participation in the Chinese rhesus macaque and Cynomolgus macaque genome projects. While exomes account for 1% of the human genome, protein coding regions contain about 85% of the pathogenic mutations. By selectively targeting DNA sequences that encode proteins, exome sequencing allows for the identification of novel gene mutations associated with both Mendelian disorders and common diseases. **Advantages** - Multiple platforms/technologies are utilized to deliver optimal results: - Complete Genomics (New!) - Ion Proton - Illumina - Cost-Effective: Our proficiency and efficiency in exome sequencing allows us to offer our customers comprehensive analysis of whole exons at lower prices than other providers. Researchers can now do more science and get more answers with limited research budgets. - Industry-leading throughput/ turnaround: Our highest throughput sequencing capacity and rapid project turnaround times enable our customers to advance their research more rapidly and effectively allowing them to attain their goals in a more timely manner - Strong bioinformatics analysis：We deliver information, not just results. Our advanced bioinformatics team provides accurate standard and advanced analysis with SNP detection over 99% for human research fields. **Platform Options** Having multiple sequencing platforms enables BGI to choose (in consultation with the customer) the most appropriate system to solve their scientific challenges. The Complete Genomics platform provides industry leading accuracy and comprehensive variation detection ideal for the research that needs: - Precise mapping of genetic recombination sites - Accurate identification of de novo disease causing mutations - Sensitive detection of somatic variants in complex cancer genomes We currently offer accurate exome sequencing at 100X on the Complete Genomics platform. Free SNP validation of 100+ loci is included to ensure the accuracy of your results, and we will redo sequencing for you at no additional cost if the percentage of correct SNP callings among validated sites falls below 95%. The Ion Proton platform has rapid sequencing speeds (only 2-4 hours for every sequencing run), and requires only 50-100 ng input DNA. Therefore, it is suitable for projects with a need for: - Extremely rapid turn-around time - Analysis of very low amount of DNA Please check out our hot rapid exome sequencing offer at 100X on the Ion Proton platform, taking you from sample to results in as little as 7 days. Illumina platform provides high throughput analysis and ample bioinformatics tools are available for a wide range of research analyses. Thus, this platform is suitable for projects with a need for - Large scale throughput - Custom bioinformatics analysis tailored for specific research needs
Whole genome re-sequencing aims to sequence the individual whose reference genome is already known. As reference genome sequences become increasingly available for many species, cataloguing sequence variations and understanding their biological consequences have become major research goals. With next-gen high-throughput sequencing technology, BGI can apply whole genome re-sequencing to your human, plant and animal, and microbe samples in order to understand genetic differences and their implications. BGI’s whole human genome sequencing can be used to study human genetics, population and evolution, human disease and clinical research, and pharmacogenomics. *Human Whole Genome Sequencing* Service Overview • Sample QC, library construction, and sequencing • High quality 30X 100PE human data delivered in standard .fastq format • Multiple bioinformatics options available. We make your research budget go further with the introduction of Whole Genome Sequencing services at a lower, industry-leading price. BGISEQ-500 based WGS services are executed with BGI’s own sequencing platform, building on our world-class sequencing experience: No compromise, just get more for less. BGISEQ-500 is a state-of-the-art sequencing system, powered by combinatorial Probe-Anchor Synthesis (cPAS) and DNA Nanoball (DNB™) technology, developed by BGI’s Complete Genomics subsidiary in Silicon Valley, California. The combination of linear amplification and DNB technology reduces the error rate while enhancing the signal. We also offer low pass whole genome sequencing as an alternative solution for array.
Low-pass Whole Genome Sequencing (WGS) provides an accurate and cost-effective solution to measuring genome-wide genetic variation. Low-pass WGS is an increasingly-popular high-throughput tool for large-scale genomics projects that traditionally have used legacy technology like genotyping arrays. NGS technology outperforms genotyping arrays by providing an order of magnitude more data, greater statistical power, and enhanced variant discovery capabilities.
Applications include genome-wide association studies, biobank profiling, and pharmacogenomics. In addition, low-pass WGS can be used to build custom reference panels to improve imputation of future samples from a specific population or disease group.
ChIP-Seq, also known as ChIP-Sequencing, is widely used to analyze protein interactions with DNA. It combines chromatin immunoprecipitation (ChIP) with massively parallel DNA sequencing to identify binding sites of DNA-associated proteins, and can be used to precisely map global binding sites for any protein of interest. ChIP sequencing offers higher resolution and more precise and abundant information in comparison with array-based ChIP-chip.
For the ChIPed DNA samples you need provide:
For the cell line samples you need provide:
Single cell RNA-Seq enables transcriptome heterogeneity study at the resolution of a single cell. It also unlocks the spatial-temporal gene expression profile with cell-by-cell resolution, which is unarchivable by standard, bulk RNA sequencing. At BGI we provide high-throughput single cell gene expression profiling service using 10x Genomics Chromium Single Cell Platform to unveil 3’ end counting of mRNA transcripts. Our turn-key solution (cell/tissue-to-report) and premade library service (library-to-data) for Single cell RNA-Seq provide flexible tool set for you depending on your preference, equipment accessibility and schedule.
BGI’s Single Cell Sequencing Solution utilizes the 10x Genomics® Chromium™ system for sample prep and library construction. Sequencing of the single cell libraries can be conducted on our proprietary DNBSEQ™ platform to ensure the downstream service quality, or the Illumina® platform (HiSeq and NovaSeq) by customer’s preference. BGI also provides sequencing services for customer self-prepared libraries using 10x Genomics® Chromium™ system Single Cell 3′ Library Construction Kit v3 and Next GEM Single Cell 3’ Library Construction Kit v3.1.
HiSeq2000 was launched as a new sequencing instrument by Illumina, Inc. in 2010, with the same principle as Genome Analyzer, using a stable reversible terminator sequencing-by-synthesis method. The technology uses four kinds containing terminal blocking group and different fluorescent signal bases to complete complementary strand synthesis, not only to ensure the high accuracy and sequencing order, but also to exclude the sequencing error caused by the repeat sequences and the homopolymer. Unlike Genome Analyzer, HiSeq2000 combines the optical systems and manufacturing processes, uses two laser sources on the Flow Cell Scan, at the same time, four cameras on the four kinds of bases were recorded to reduce signal interference between different bases improved sequencing accuracy. HiSeq2000 adopts dual surface imaging technology, Flow Cell effective area increased, thereby increasing the throughput, reducing sequencing costs.
|Read Length||Single Flow Cell Output||Single Flow Cell Run Time||Dual Flow Cell Output||Dual Flow Cell Run Time|
|1×35||47-52Gb||1.5 days||95-105Gb||2 days|
|2×50||135-150Gb||4.5 days||270-300Gb||5.5 days|
|2×100||270-300Gb||8.5 days||540-600Gb||11 days|
|Performance||2×50bp Q30≥85%, 2×100bp Q30≥80%|
*Install specifications for HiSeq sequencers with an Illumina PhiX library and cluster densities between 610-678 K/mm2 that pass filtering on a HiSeq system using TruSeq v3 Cluster and SBS kits for HiSeq. Performance may vary based on sample quality, cluster density, and other experimental factors.
HiSeq2500 (the upgraded version of Illumina HiSeq2000 sequencing instrument) was launched in 2012. There are 20 Hsieq2500 in BGI and distributed around the world. Compared with HiSeq2000, HiSeq2500 has two sequencing modes: High Output mode and Rapid mode. High Output mode has the same pattern as HiSeq2000 sequencing instrument; there is no change in sequencing reagents and Flow Cell. Rapid mode uses the new Flow Cell and sequencing reagents, shortening sequencing time, sequencing read lengths up to 150bp.
High Output Mode*
|Read Length||Dual Flow Cell||Single Flow Cell||Dual Flow Cell Run Time|
|Performance||2×50bp Q30≥85%, 2×100bp Q30≥80%|
|Read Length||Dual Flow Cell||Single Flow Cell||Dual Flow Cell Run Time|
|Performance||2×50bp Q30≥85%, 2×100bp Q30≥80%, 2×150bp Q30≥75%|
*Install specifications based on Illumina PhiX control library at supported cluster densities (between 610-678 K clusters/mm2 passing filter using TruSeq v3 or 700-820 K clusters/mm2 passing filter using TruSeq Rapid kits). Run times for rapid run mode correspond to onboard cluster generation(1.5 hours) and sequencing; for high-output mode, run times correspond to sequencing only, not include Flow Cell Preparation time(4-5hours). Performance may vary based on sample quality, cluster density, and other experimental factors. HiSeq2000 instruments prior to serial number 700895, rapid mode to extend the running time of approximately 15 hours when upgraded.
Miseq (Illumina) is a new generation of miniaturized sequencing instrument (bench-top) launched on February 2011, which uses a chemical method based on Illumina TruSeq technology that nucleotide sequencing-by-synthesis by reversible terminator. Compared with Hiseq2000, the unparalleled accuracy of next-generation sequencing reagents, transitory sequencing time by new fluid system are the main advantages, although the throughput of a run is low.
|Read Length||Run Time||Throughput||Quality|
|2×150bp||About 24 hours||4.5-5.1Gb||Q30>80%|
|2×250bp||About 39 hours||7.5-8.5Gb||Q30>70%|
(1)The above performance is based on Miseq sequencing V2 reagent. V1 reagent only supports 2x150bp, runs about 27 hours, 1.5-2Gb throughput, Q30>80%. But V1 reagent is no longer ordered.
(2)This data is based on Illumina control libraries PhiX (a balanced representation of A, T, G, and C nucleotides). The appropriate clusters density is 900-1200K/mm2, and 880-965K/mm2 after PF. But different sample sequencing results by their own properties.
Metagenomics is the study of genomes contained within an entire microbial community. This technology has opened up a new era in the study of microbial diversity with direct access to the genomes of numerous non-cultivatable microorganisms in their natural habitat. Metagenomic sequencing analyzes microbial community diversity, gene composition and function, as well as metabolic pathways associated with the specific environment. This approach has been applied to environmental studies as well as biomarker research.
Specific custom analysis will be determined based upon customer requirements.
The standard turnaround time for the whole workflow (including library construction, sequencing and bioinformatics analysis) is 40-70 business days.
Generate 1G clean data at minimum
Scientific research through traditional transcriptome analysis of early-stage embryos, stem cells, cancers, immune cells, and developing neurons is limited, because the amount of sample that is obtained does not meet the minimum requirements for traditional NGS, which is probably due to extremely little or immensely high heterogeneity. Thus, the need for single-cell transcriptome analysis is particularly urgent. Single-cell RNA-Seq quantifies the mRNA of a single cell through single-tube reverse transcription and PCR amplification, allowing several micrograms of cDNA to be collected for traditional library construction and Hiseq2000 sequencing. Single-cell RNA-Seq is a novel application of RNA-Seq that is capable of sequencing a single cell or infinitesimal amounts of sample.
|Level A||Mammalian oocyte, single blastomere from one-cell stage to eight-cell stage (e.g. single cell of human/mouse early-stage embryo)||Has been tested, success rate > 90%|
|Level B||Single mammalian cells from morula to blastula; both free single cells and cell lines with diameters greater than 10 μm (e.g. circulating tumor cells)||No test has been performed; theoretically executable with relatively low risk|
|Level C||Normal tissue cells||No test has been performed; lacks theoretical support, therefore high risk|
|Level D||Special tissues/structural cells, e.g. cells from vegetative pole of ovipara||Has been tested,impracticable|
The average turnaround time for RNA-Seq on 50 cells is about 40 workdays.
Completion is indicated by the number of clean reads. The goals are individualized for each project.
Single cell sequencing can facilitate the elucidation of cell lineage relationships. The major applications of this technique include profiling scarce clinical samples (i.e. circulating tumor cells), pre-implantation genetic diagnosis, embryonic development research, and tumor progression analysis.
Advancing the possibilities of single cell sequencing in human disease research, we have developed an innovative end-to-end solution for genomics analysis at the single cell level. Within this solution, multiple displacement amplification (MDA) has been further enhanced and incorporated into BGI’s whole genome amplification (WGA) protocol, which enables uniform amplification of genomic DNA from single cells (from as little as one cell) with negligible sequence bias and maximized genome coverage.
BGI has sequenced hundreds of cells, and the results from applying the new single-cell sequencing method to identify the genetic characteristics of essential thrombocythemia and clear cell renal cell carcinoma have been published in the journal Cell.
91 PE or 101 PE
Recommended Data Amount:
≥ 30X for whole genome resequencing. Sequencing depth can be customized according to the research purpose.
The standard turnaround time for the workflow is approximately 57 business days for whole genome sequencing of 100 samples at 30X coverage.
Effective mean depth of each sample should be no less than required in the contract.
BGI Genomics has not received any endorsements.